INSTITUT NATIONAL DU CANCER GIP

Their core work

INCa is France's national cancer agency, responsible for coordinating national cancer research policy, funding translational cancer research programmes, and aligning French cancer strategy with European initiatives. It acts as a policy and funding body that channels national and regional research investments into cancer prevention, diagnostics, and treatment. Within H2020, INCa primarily contributes by co-funding and coordinating transnational cancer research calls through ERA-NET mechanisms, and by supporting the clinical translation of advanced therapies like CAR-T and TCR-engineered cell therapies.

What they specialise in

How they've shifted over time

INCa's early H2020 involvement (2015-2020) centred on cancer genomics infrastructure — next-generation sequencing, liquid biopsies, and establishing clinical validity standards for diagnostic tools. From 2021 onward, their focus shifted decisively toward advanced therapeutic modalities, particularly CAR-T and TCR-engineered cell therapies, alongside sustained investment in transnational research coordination through TRANSCAN-3. This mirrors the broader European shift from precision diagnostics toward personalised immunotherapies.

INCa is moving from diagnostic standardisation toward ensuring equitable access to advanced cell and gene therapies across Europe, making them a strong partner for ATMP-related consortia.

How they like to work

INCa participates exclusively as a partner, never as coordinator — consistent with its role as a national funding and policy body that supports rather than leads research execution. With 84 unique partners across 25 countries, they operate in large, pan-European consortia typical of ERA-NET structures. This makes them an accessible partner for organisations seeking alignment with French national cancer research priorities and co-funding mechanisms.

INCa has collaborated with 84 unique partners across 25 countries, reflecting its role as a national node in pan-European cancer research networks. Their geographic reach spans virtually all EU member states, with particularly strong connections through the TRANSCAN ERA-NET consortia.

What sets them apart

INCa is not a research lab — it is France's central cancer policy and funding agency, which gives it a unique convening power. Partnering with INCa provides direct alignment with French national cancer strategy and access to co-funding through ERA-NET mechanisms. For consortium builders, INCa brings institutional weight, regulatory insight into ATMP and diagnostic frameworks, and the ability to mobilise French research networks.

Highlights from their portfolio

• TRANSCAN-3
  Largest funding (EUR 798,618) and a continuation of TRANSCAN-2, representing INCa's flagship role in sustaining pan-European translational cancer research coordination through 2027.
• T2EVOLVE
  Marks INCa's strategic entry into CAR-T and TCR cell therapy, addressing manufacturing (GMP), preclinical validation, and patient access — a significant expansion from their traditional policy role.